BCG-Mediated Bladder Cancer Immunotherapy: Identifying Determinants of Treatment Response Using a Calibrated Mathematical Model

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Rentsch, Cyrill A ^a,b   Biot, Claire ^b,c,d   Gsponer, Joël R ^a,b   Bachmann, Alexander ^a   Albert, Matthew L ^b,d   Breban, Romulus ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b INSTITUT PASTEUR   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADAPTIVE IMMUNITY; ARTICLE; BLADDER CANCER; BLADDER MUCOSA; CALIBRATION; CANCER IMMUNOTHERAPY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG INSTILLATION; IN VITRO STUDY; INDUCTION CHEMOTHERAPY; INNATE IMMUNITY; MATHEMATICAL MODEL; PROBABILITY; SENSITIVITY ANALYSIS; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; TUMOR CELL;

BCG VACCINE; HUMANS; IMMUNOTHERAPY; MODELS, THEORETICAL; URINARY BLADDER NEOPLASMS;

EID: 84874511871     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056327     Document Type: Article

References (22)

1. Morales A, Eidinger D, (1976) Bacillus Calmette-Guerin in the treatment of adenocarcinoma of the kidney. J Urol 115: 377-380.
2. Breban R, Bisiaux A, Biot C, Rentsch CA, Bousso P, et al. (2012) Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response. OncoImmunology 1: 1-9.
3. Breart B, Lemaitre F, Celli S, Bousso P, (2008) Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest 118: 1390-1397.
4. Cao Y, Gillespie DT, Petzold LR, (2006) Efficient step size selection for the tau-leaping simulation method. J Chem Phys 124: 044109.
5. Bisiaux A, Thiounn N, Timsit MO, Eladaoui A, Chang HH, et al. (2009) Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer. J Urol 181: 1571-1580.
6. Cooper AM, (2009) Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27: 393-422.
7. Biot C, Rentsch CA, Gsponer JR, Birkhauser FD, Jusforgues-Saklani H, et al. (2012) Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer. Sci Transl Med 4: 137ra172.
8. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, et al. (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163: 1124-1129.
9. van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV, (2003) Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 44: 429-434.
10. Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D, et al. (1991) A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J Urol 146: 32-35.
11. Losa A, Hurle R, Lembo A (2000) Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol 163: 68-71; discussion 71-62.
12. Mack D, Frick J, (1995) Low-dose bacille Calmette-Guerin (BCG) therapy in superficial high-risk bladder cancer: a phase II study with the BCG strain Connaught Canada. Br J Urol 75: 185-187.
13. Martinez-Pineiro JA, Flores N, Isorna S, Solsona E, Sebastian JL, et al. (2002) Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 89: 671-680.
14. Ojea A, Nogueira JL, Solsona E, Flores N, Gomez JM, et al. (2007) A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol. 52: 1398-1406.
15. Agrawal MS, Agrawal M, Bansal S, Agarwal M, Lavania P, et al. (2007) The safety and efficacy of different doses of bacillus Calmette Guerin in superficial bladder transitional cell carcinoma. Urology 70: 1075-1078.
16. Andius P, Fehrling M, Holmang S, (2005) Intravesical bacillus Calmette-Guerin therapy: experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int 96: 1290-1293.
17. de Boer EC, Rooyakkers SJ, Schamhart DH, de Reijke TM, Kurth KH, (2005) BCG dose reduction by decreasing the instillation frequency: effects on local Th1/Th2 cytokine responses in a mouse model. Eur Urol 48: 333-338.
18. Bassi P, Spinadin R, Carando R, Balta G, Pagano F, (2000) Modified induction course: a solution to side-effects? Eur Urol 37Suppl 1: 31-32.
19. Bunimovich-Mendrazitsky S, Shochat E, Stone L, (2007) Mathematical model of BCG immunotherapy in superficial bladder cancer. Bull Math Biol 69: 1847-1870.
20. Bunimovich-Mendrazitsky S, Goltser Y, (2011) Use of quasi-normal form to examine stability of tumor-free equilibrium in a mathematical model of BCG treatment of bladder cancer. Math Biosci Eng 8: 529-547.
21. Bunimovich-Mendrazitsky S, Claude Gluckman J, Chaskalovic J, (2011) A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer. J Theor Biol 277: 27-40.
22. Bunimovich-Mendrazitsky S, Byrne H, Stone L, (2008) Mathematical model of pulsed immunotherapy for superficial bladder cancer. Bull Math Biol 70: 2055-2076.